[1] Deeb W, Malaty IA, Mathews CA. Tourette disorder and other tic disorders[M]//Handb Clin Neurol: 165. Elsevier, 2019: 123-153.
[2] Liu ZS, Cui YH, Sun D, et al. Current status, diagnosis, and treatment recommendation for tic disorders in China[J]. Front Psychiatry, 2020, 11: 774.
[3] Wang X, Liu X, Chen L, et al. The inflammatory injury in the striatal microglia-dopaminergic-neuron crosstalk involved in Tourette syndrome development[J]. Front Immunol, 2023, 14: 1178113.
[4] Naro A, Billeri L, Colucci VP, et al. Brain functional connectivity in chronic tic disorders and Gilles de la Tourette syndrome[J]. Progress in Neurobiology, 2020, 194: 101884.
[5] Qian QQ, Tan QQ, Sun D, et al. A pilot study on plasma and urine neurotransmitter levels in children with tic disorders[J]. Brain Sci, 2022, 12(7): 880.
[6] Ercan-Sencicek AG, Stillman AA, Ghosh AK, et al. L-Histidine decarboxylase and Tourette's syndrome[J]. N Engl J Med, 2010, 362(20): 1901-1908.
[7] Lintas C, Sacco R, Azzarà A, et.al. Genetic dysruption of the histaminergic pathways: A novel deletion at the 15q21.2 locus associated with variable expressivity of neuropsychiatric disorders[J]. Genes, 2022, 13(10): 1685.
[8] Fernandez TV, Sanders SJ, Yurkiewicz IR, et al. Rare copy number variants in tourette syndrome disrupt genes in histaminergic pathways and overlap with autism[J]. Biol Psychiatry, 2012, 71(5): 392-402.
[9] Rapanelli M, Frick L, Bito H, et al. Histamine modulation of the basal ganglia circuitry in the development of pathological grooming[J]. PNAS, 2017, 114(25): 6599-6604.
[10] Castellan Baldan L, Williams KA, Gallezot JD, et al. Histidine decarboxylase deficiency causes Tourette syndrome: Parallel findings in humans and mice[J]. Neuron, 2014, 81(1): 77-90.
[11] Rapanelli M, Frick LR, Pogorelov V, et al. Dysregulated intracellular signaling in the striatum in a pathophysiologically grounded model of Tourette syndrome[J]. Eur Neuropsychopharmacology, 2014, 24(12): 1896-1906.
[12] Pittenger C. Histidine decarboxylase knockout mice as a model of the pathophysiology of Tourette syndrome and related conditions[M]//Handb Exp Pharmacol, 2017: 189-215.
[13] Jindachomthong K, Yang C, Huang Y, et al. White matter abnormalities in the Hdc knockout mouse, a model of tic and OCD pathophysiology[J]. Front Mol Neurosci, 2022, 15:1037481.
[14] Shitova AD, Zharikova TS, Kovaleva ON, et al. Tourette syndrome and obsessive-compulsive disorder: A comprehensive review of structural alterations and neurological mechanisms[J]. Behav Brain Res, 2023, 453:114606.
[15] Jackson SR, Sigurdsson HP, Dyke K, et.al. The role of the cingulate cortex in the generation of motor tics and the experience of the premonitory urge-to-tic in Tourette syndrome[J]. J Neuropsychol, 2021,15(3):340-362.
[16] Kalanithi PSA, Zheng W, Kataoka Y, et al. Altered parvalbumin-positive neuron distribution in basal ganglia of individuals with Tourette syndrome[J]. PNAS, 2005, 102(37): 13307-13312.
[17] Liu H, Hua H, Kang T. White matter alterations predict outcomes of comprehensive behavioral intervention for tics in children with Tourette syndrome: A diffusion MRI study[J]. J Psychiatr Res, 2024,175:418-424.
[18] Rapanelli M. The magnificent two: Histamine and the H3 receptor as key modulators of striatal circuitry[J]. Prog Neuro-Psychopharmacol Biol Psychiatry, 2017, 73: 36-40.
[19] Ellender TJ, Huerta-Ocampo I, Deisseroth K, et al. Differential modulation of excitatory and inhibitory striatal synaptic transmission by histamine[J]. J Neurosci, 2011, 31(43): 15340-15351.
[20] Zhuang QX, Xu HT, Lu XJ, et al. Histamine excites striatal dopamine D1 and D2 receptor-expressing neurons via postsynaptic H1 and H2 receptors[J]. Mol Neurobiol, 2018, 55(10): 8059-8070.
[21] Xu J, Pittenger C. The histamine H3 receptor modulates dopamine D2 receptor-dependent signaling pathways and mouse behaviors[J]. J Biol Chem, 2023, 299(4):104583.
[22] Carthy E, Ellender T. Histamine, Neuroinflammation and Neurodevelopment: A review[J]. Front Neurosci, 2021,15:680214.
[23] Han S, Márquez-Gómez R, Woodman M, et al. Histaminergic control of corticostriatal synaptic plasticity during early postnatal development[J]. J Neurosci, 2020, 40(34): 6557-6571.
[24] Yu J, Yao X, Zhang X, et al. New insights of metabolite abnormalities in the thalamus of rats with iminodiproprionitrile-induced tic disorders[J].Front Neurosci, 2023, 17:1201294.
[25] Augustine F, Singer HS. Merging the pathophysiology and pharmacotherapy of Tics[J]. Tremor and Other Hyperkinetic Movements, 2019, 8(0): 595.
[26] Maia TV, Conceição VA. Dopaminergic disturbances in Tourette syndrome: An integrative account[J]. Biol Psychiatry, 2018, 84(5): 332-344.
[27] Müller-Vahl KR, Berding G, Brücke T, et al. Dopamine transporter binding in Gilles de la Tourette syndrome[J]. J Neurol, 2000, 247(7): 514-520.
[28] Anderson GM. Brain monoamines and amino acids in gilles de la Tourette's syndrome: A preliminary study of subcortical regions[J]. Arch Gen Psychiatry,1992, 49(7): 584.
[29] Rapanelli M, Frick L, Pogorelov V, et al. Histamine H3R receptor activation in the dorsal striatum triggers stereotypies in a mouse model of tic disorders[J]. Transl Psychiatry,2017, 7(1): e1013-e1013.
[30] Varaschin RK, Osterstock G, Ducrot C, et al. Histamine H3 receptors decrease dopamine release in the ventral striatum by reducing the activity of striatal cholinergic interneurons[J]. Neuroscience, 2018, 376: 188-203.
[31] Venkatachalam K, Eissa N, Awad MA, et al. The histamine H3R and dopamine D2R/D3R antagonist ST-713 ameliorates autism-like behavioral features in BTBR T+tf/J mice by multiple actions[J]. Biomed Pharmacother, 2021, 138:111517.
[32] Ma Q, Jiang L, Chen H, et al. Histamine H₂ receptor deficit in glutamatergic neurons contributes to the pathogenesis of schizophrenia[J]. PNAS, 2023, 120(9): e2207003120.
[33] Dere E, De Souza-Silva MA, Spieler RE, et al. Changes in motoric, exploratory and emotional behaviours and neuronal acetylcholine content and 5-HT turnover in histidine decarboxylase-KO mice[J]. Eur J Neurosci, 2004, 20(4): 1051-1058.
[34] Pfanzagl B, Pfragner R, Jensen-Jarolim E. Histamine via histamine H1 receptor enhances the muscarinic receptor-induced calcium response to acetylcholine in an enterochromaffin cell model[J]. Clin Exp Pharmacol P, 2022, 49 (10): 1059-1071.
[35] Nirogi R, Benade V, Daripelli S, et al. Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: Pharmacological and neurochemical characterisation[J]. Psychopharmacology, 2021, 238 (6): 1495-1511.
[36] Johnson KA, Worbe Y, Foote KD, et al. Tourette syndrome: Clinical features, pathophysiology, and treatment[J]. Lancet Neurol, 2022, 22 (2): 147-158.
[37] Kumar A, Williams MT, Chugani HT. Evaluation of basal ganglia and thalamic inflammation in children with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection and tourette syndrome: A positron emission tomographic(PET) study using¹¹ C-[R]-PK11195[J]. J Child Neurol, 2015, 30(6): 749-756.
[38] Yanhui C. Neuroinflammation in a rat model of Tourette Syndrome[J]. Front Behav Neurosci, 2022, 16.
[39] Dong H, Wang Y, Zhang X, et al. Stabilization of brain mast cells alleviates LPS-induced neuroinflammation by inhibiting microglia activation[J]. Front Cell Neurosci, 2019, 13:191.
[40] Barata-Antunes S, Cristóvão AC, Pires J, et al. Dual role of histamine on microglia-induced neurodegeneration[J].Bba-mol Basis Dis, 2017, 1863 (3): 764-769.
[41] Frick L, Rapanelli M, Abbasi E, et al. Histamine regulation of microglia: Gene-environment interaction in the regulation of central nervous system inflammation[J]. Brain Behav Immun, 2016, 57: 326-337.
[42] Zhang W, Zhang X, Zhang Y, et al. Histamine induces microglia activation and the release of proinflammatory mediators in rat brain via H1R or H4R[J]. J Neuroimmune Pharmacol, 2020, 15(2): 280-291.
[43] Zhu J, Qu C, Lu X, et al. Activation of microglia by histamine and substance P[J]. Cell Physiol Biochem,2014, 34(3): 768-780.
[44] Ferreira R, Santos T, Gonçalves J, et al. Histamine modulates microglia function[J]. J Neuroinflammation, 2012, 9: 90.
[45] Olah M, Biber K, Vinet J, et al. Microglia phenotype diversity[J]. CNS Neurol Disord Drug Targets,2011,10(1): 108-118.
[46] Wolf SA, Boddeke HWGM, Kettenmann H. Microglia in physiology and disease[J]. Annu Rev Physiol, 2017, 79(1): 619-643.
[47] Godar SC, Mosher LJ, Di Giovanni G, et al. Animal models of tic disorders: A translational perspective[J]. J Neurosci Meth, 2014, 238: 54-69.
[48] Gober HJ, Li KH, Yan K, et al. Hydroxyzine use in preschool children and its effect on neurodevelopment: A population-based longitudinal study[J]. Front Psychiatry, 2022, 12: 721875.
[49] Rapanelli M, Frick L, Jindachomthong K, et al. Striatal signaling regulated by the H3R histamine receptor in a mouse model of tic pathophysiology[J]. Neuroscience, 2018, 392: 172-179.
[50] Wang J, Liu B, Sun F, et al. Histamine H3R antagonist counteracts the impaired hippocampal neurogenesis in Lipopolysaccharide-induced neuroinflammation[J]. Int Immunpharmacol, 2022, 110:109045.
[51] Hartmann A, Worbe Y, Arnulf I. Increasing histamine neurotransmission in Gilles de la Tourette syndrome[J]. J Neurol, 2012, 259(2): 375-376.
[52] Ricketts EJ, Swisher V, Greene DJ, et al. Sleep disturbance in Tourette＇s disorder: Potential underlying mechanisms[J]. Curr Sleep Med Rep, 2023, 9(1):10-22.
[53] Pittenger C. The histidine decarboxylase model of tic pathophysiology:A new focus on the histamine H₃ receptor[J]. Br J Pharmacol,2020, 177(3): 570-579.
[54] Zhou P, Homberg JR, Fang Q, et al. Histamine-4 receptor antagonist JNJ7777120 inhibits pro-inflammatory microglia and prevents the progression of parkinson-like pathology and behaviour in a rat model[J]. Brain Behav Immun, 2019, 76: 61-73.